# Petros Pharmaceuticals (PTPI) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/PTPI
## Company Profile
- Ticker: PTPI
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 0.005 USD
- Market cap: Not available USD
- Last updated: 2026-09-03
## Business Overview
Petros Pharmaceuticals is a specialty pharmaceutical company focused on men’s health and self-care products, including sexual-health-related therapies. Its business is centered on consumer-accessible specialty medicines rather than classic biotech discovery.
## Why The Stock Is Moving

As of Sep 3, 2026, PTPI closed up 6.38% at $0.0050. No new same-company headline was identified in the current news window.

## Geographic Base

Petros is headquartered in the United States and listed on NASDAQ. It sits in specialty pharma and men’s health.

## Business Model

The company depends on commercial execution, regulatory pathways, and the ability to expand access to a narrow product set. Investors usually watch product adoption, label strategy, and cash management.

## Landscape Position

Petros occupies a niche men’s-health specialty-pharma position. It is less about clinical-stage binary risk and more about commercial access and brand execution.

## Future Catalysts

- Petros’s catalysts are men’s-health and sexual-health commercialization, plus any strategic update that clarifies the company’s future. The market will care about whether the product base can stabilize.

## Recent News
- 2022-07-28 14:27 EST — [Petros Pharmaceuticals Responds to Fraudulent Press Release](https://biopharmsignal.com/news/PTPI/petros-pharmaceuticals-responds-to-fraudulent-press-release-cdf0f94a) — Source: Petros Pharmaceuticals
- 2022-07-19 13:15 EST — [Petros Pharmaceuticals Kicks Off Social Media Campaign with Celebrity Physician Dr. Drew Pinsky](https://biopharmsignal.com/news/PTPI/petros-pharmaceuticals-kicks-off-social-media-campaign-with-celebrity-physician--bb0a7b2e) — Source: Petros Pharmaceuticals
- 2022-05-16 21:00 EST — [Petros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/PTPI/petros-pharmaceuticals-reports-first-quarter-2022-financial-results-and-provides-14b1f83b) — Source: Petros Pharmaceuticals
- 2022-05-03 13:23 EST — [Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company’s Novel Topical Investigational Treatment for Peyronie’s Disease Which Impacts More Than 1 in 10 Men in the US](https://biopharmsignal.com/news/PTPI/petros-pharmaceuticals-to-pursue-505-b-2-pathway-for-h-100-company-s-novel-topic-d8e7f260) — Source: Petros Pharmaceuticals
- 2022-04-28 01:25 EST — [Petros Pharmaceuticals to Present at the Planet MicroCap Showcase 2022](https://biopharmsignal.com/news/PTPI/petros-pharmaceuticals-to-present-at-the-planet-microcap-showcase-2022-5a84e7da) — Source: Petros Pharmaceuticals